The flow diagram (Figure 1) shows the results from the literature search and the study selection process. Nineteen studies met the eligibility criteria.
Table 2 displays the nineteen papers included in this review.
According to the COSMIN checklist, all studies included in this review showed an adequate-to-doubtful quality. The majority of clinical trials had a high-to-moderate risk of bias. This is due to the design of the included studies, mainly case reports and observational studies. According to the “Chauvenet’s criterion”, almost all data lie within one standard deviation of the mean and they can be considered reliable, without the risk of outliers (see Figure 2).
In the included studies, 221 patients were diagnosed with PDPH and treated with regional anesthesia: 97 received sphenopalatine ganglion block, 58 received greater occipital nerve block, while the others patients received a combination of nerve blocks (42 received both SPNB and GONB in Xavier J et al 2020, 24 received both GONB and LONB in Naja et al 2009). All participants were female with mean age of 32.87 ± 5.16 years (Puthenveettil N et al 2018, Matute E et al 2008, Niraj G et al 2014 did not reported age of participants).
The largest studies involved 42 patients (Cohen S et al, 2018; Xavier J et al, 2020), while the smallest consisted of single case report (Cardoso JL et al, 2017; Channabasappa SM et al, 2017; Goncalves et al, 2018; Murphy CA et al, 2020; Singla D et al, 2018; Akin Takmaz S et al, 2009). All analyzed studies were conducted in inpatient settings.
Patients underwent various operation; the most common surgeries were labor pain/delivery (8 studies: Cohen S et al, 2018; Furtado et al, 2018; Goncalves et al, 2018; Kent S et al, 2016; Puthenveettil N et al, 2018; Xavier J et al, 2020; Matute E et al, 2008; Niraj G et al, 2014; Türkyilmaz EU et al, 2016), followed by gynecological (3 studies: Channabasappa SM et al, 2017; Dubey P et al, 2018; Naja et al 2009), abdominal (2 studies: Akin Takmaz S et al, 2009; Matute E et al, 2008), diagnostic (2 studies: Kent S et al, 2015; Murphy CA et al, 2020), urological (2 studies: Cardoso JL et al, 2017; Dubey P et al, 2018), and orthopedic procedures (2 studies: Naja et al 2009; Singla D et al, 2018). Two studies (Jespersen MS et al, 2020; Akyol F et al, 2015) did not report the intervention.
Concerning anesthesia technique, peridural anesthesia was performed 10 times (Cardoso JL et al, 2017; Cohen S et al, 2018; Furtado et al, 2018; Goncalves et al, 2018; Jespersen MS et al, 2020; Kent S et al, 2016; Puthenveettil N et al, 2018; Xavier J et al, 2020; Matute E et al, 2008; Niraj G et al, 2014); subarachnoid anesthesia was reported in ten studies (Dubey P et al, 2018; Jespersen MS et al, 2020; Singla D et al, 2018; Xavier J et al, 2020; Akin Takmaz S et al, 2009; Akyol F et al, 2015; Matute E et al, 2008; Naja et al 2009; Niraj G et al, 2014; Türkyilmaz EU et al, 2016); combined spinal-epidural (CSE) technique was performed in Channabasappa SM et al 2017, Furtado et al 2018 and Xavier J et al 2020; finally in two studies (Kent S et al, 2015; Murphy CA et al, 2020) patients underwent diagnostic lumbar puncture (LP).
Not all studies reported the type of needle used to administer anesthesia. Where data are available, peridural was administered using 16-gauge or 18-gauge Tuohy needles; 25-gauge or 27-gauge Quincke and 27-gauge Whitacre needles were used for spinal anesthesia. In Türkyilmaz EU et al 2016, spinal blocks were performed using 26-gauge needles with an atraumatic bevel (Atraucan®, B-Braun, Germany).
PDPH appeared between the first (Furtado et al, 2018; Kent S et al, 2016;Murphy CA et al, 2020; Akin Takmaz S et al, 2009; Matute E et al, 2008) and seventh (Cardoso JL et al, 2017) day after the anesthetic procedure.
In some studies, patients referred the associated symptoms of nausea (Cardoso JL et al, 2017; Cohen S et al, 2018; Dubey P et al, 2018; Goncalves et al, 2018; Murphy CA et al, 2020; Naja et al, 2009), vomiting (Cardoso JL et al, 2017; Dubey P et al, 2018; Naja et al, 2009), photophobia (Cohen S et al, 2018; Dubey P et al, 2018; Murphy CA et al, 2020; Naja et al, 2009), phonophobia (Murphy CA et al, 2020: Naja et al, 2009), dizziness (Goncalves et al, 2018; Naja et al, 2009), blurry vision (Kent S et al, 2015; Naja et al, 2009), loss of appetite (Naja et al, 2009) and ataxia (Naja et al, 2009).
Conservative treatment was administered and consisted of bed rest and postural measures, oral and intravenous hydration, caffeine and multimodal analgesia (acetaminophen, NSAIDs and opioids). Three studies (Cohen S et al, 2018; Dubey P et al, 2018; Kent S et al, 2016) did not report conservative management.
Peripheral nerve blocks. Sphenopalatine ganglion block was performed using cotton-tip applicators dipped into local anesthetic: 0.5% levobupivacaine (Cardoso JL et al, 2017), 2% lidocaine (Kent S et al, 2015; Kent S et al, 2016; Puthenveettil N et al, 2018), 4% lidocaine (Cohen S et al, 2018; Murphy CA et al, 2020), 0.75% ropivacaine (Furtado et al, 2018; Goncalves et al, 2018), and a mixture of 4% lidocaine and 0.5% ropivacaine in Jespersen MS et al 2020. In two studies (Channabasappa SM et al, 2017; Singla D et al 2018), 0.75% ropivacaine was respectively injected using a spinal needle and an epidural catheter. Xavier J et al 2020 performed SPGB with 1% ropivacaine both using cotton-tip applicators or an epidural catheter. Dubey P et al 2018 used intranasal lidocaine spray.
Greater occipital nerve block consisted of injecting local anesthetic lateral to external occipital protuberance. Akin Takmaz S et al 2009 used 0.5% ropivacaine, Akyol F et al 2015 0.25% levobupivacaine, Matute E et al 2008 0.5% bupivacaine and triamcinolone, Naja et al 2009 1% lidocaine, Niraj G et al 2014 1% lidocaine and dexamethasone, Türkyilmaz EU et al 2016 0.25% levobupivacaine and dexamethasone, and Xavier J et al 2020 1% ropivacaine.
In Naja et al 2009, lesser occipital nerve block was performed injecting 1% lidocaine at the superior third of the posterior limit of the sternocleidomastoid muscle.
Table 3 summarizes the techniques used.
Pain Intensity. Different investigators recorded this outcome on different scales and at different intervals. We normalized all NRS to a zero to 10 range (see Table 4). The majority of authors reported pain intensity before performing SPGB, GONB or LONB and 1, 24 and 48 hours after treatment.
Pain intensity before the procedure was reported in 13 studies, which involved 170 patients with PDPH. All participants reported NRS ≥ 8, except in Akyol F et al, 2015 (NRS 6.26) and Naja et al 2009 (NRS 7).
After 1 hour, NRS was lower than 4 in all studies except for Jespersen MS et al 2020. NRS ≥ 4 was only reported in Kent S et al 2015 and Naja et al 2009 at 24 hours after nerve block, and in Murphy CA et al 2020 at 48 hours.
Pain intensity before the procedure was 8.59 ± 1.06. NRS was 1.05 ± 1.28 after 1 hour, 1.78 ± 1.83 after 24 hours, and 1.71 ± 1.79 after 48 hours.
Cohen S et al 2018 did not reported pain evaluation. 71.4% of patients experienced headache relief 1 hour after the SPGB after the EBP treatment. After 24 and 48 hours, SPGB was effective in 85.7% and 92.9% of cases, respectively.
We made the hypothesis that these data be well described by a single number, determining the weighted mean of the measurements. We performed Chi-square test using 95% confidence level for available data before (x2/ν = 6.57/5 ≈ 1.31; α = 0.25), and at 1 hour (x2/ν = 0.44/4 ≈ 0.11; α = 0.98), 24 hours (x2/ν = 6.06/6 ≈ 1.01; α = 0.42) and 48 hours (x2/ν = 0.57/1 ≈ 0.57; α = 0.45) after peripheral nerve blocks. We have therefore no good reason to reject the hypothesis and conclude that the measurements are consistent with each other.
We performed Student t-test between NRS before treatment and after 1 hour (p < 0.05), 24 hours (p < 0.05), and 48 hours (p < 0.05). No statistical difference was found between NRS after 1 and 24 hours (p = 0.37), and after 24 and 48 hours (p = 0.52).
Adverse events (AEs). An adverse event is defined as any undesirable experience associated with the use of a medical product in a patient. No AE was reported after the execution of SPGB, GONB or LONB, except in Jespersen MS et al 2020 and Murphy CA et al 2020. In the first study, AEs were recorded in 10 patients: one patient reported severe nasal discomfort and nausea during the insertion, and five patients reported light pain or discomfort during the insertion. Throat discomfort, light left ear pain during insertion and tingling sensation in the left cheek during insertion were also reported after receiving the block. In Murphy CA et al 2020, the patient described an unpleasant taste after dropping the lidocaine into nostril.
Other therapeutic interventions. 38 patients needed to receive a second or more nerve block, SPGB, GONB or LONB, and 30 patients an EBP.
In five patients, the procedure had to be repeated after 1 hour in Dubey P et al 2018. A second SPGB was performed in 2 patient after 24 hours with relief in the next hour (Furtado et al, 2018); other two patients received EBP. In Jespersen MS et al 2020 from 1 hour to 7 days after the block, 13 patients received a rescue block and 10 received an EBP.
Xavier J et al 2020 reported 2 courses in 15 patients; among these, nine patients required EBP due to treatment failure with peripheral nerve block. Kent S et al 2015 reported EBP after 12 hours with complete resolution of headache.
A total of 3 patients treated with GONB (Akin Takmaz S et al, 2009; Türkyilmaz EU et al 2016) received a second nerve block with pain resolution. Türkyilmaz EU et al 2016 reported a patient’s NRS not change two hours after primary GONB and an EBP was performed. Following the occipital block in Naja et al 2009, the headache was completely relieved in 68.4% of patients after one to two injections; the remaining 31.6% of patients experienced relief only after the third or fourth injection. In Niraj G et al 2014, six patients reported partial resolution of the symptoms after GONB and all received EBP.